Firocoxib
![]() | |
![]() | |
Systematic (IUPAC) name | |
---|---|
3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one | |
Clinical data | |
Trade names | Equioxx; Previcox |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | 189954-96-9 |
ATCvet code | QM01AH90 (WHO) |
PubChem | CID 208910 |
ChemSpider |
181008 ![]() |
UNII |
Y6V2W4S4WT ![]() |
KEGG |
D03712 ![]() |
ChEBI | CHEBI:76136 |
ChEMBL |
CHEMBL69998 ![]() |
Chemical data | |
Formula | C17H20O5S |
Molar mass | 336.402 g/mol |
| |
| |
(verify) |
Firocoxib (INN; brand names Equioxx and Previcox) is a non-steroidal anti-inflammatory drug of the COX-2 inhibitor (coxib) class, currently approved for use in dogs and horses. Firocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses.[1] Firocoxib is not intended or approved for use in human medicine.[2]
References
- ↑ "New NSAID Equioxx (firocoxib) Approved by USEF". The Horse. July 2, 2007. Retrieved 2008-04-18.
- ↑ Equioxx, European Medicines Agency
|
This article is issued from Wikipedia - version of the Tuesday, April 19, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.